Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF) announced that detailed results from its pivotal trial evaluating the next-generation B-Series OCT with ImgAssist AI 2.0 for breast-conserving surgery (BCS) will be presented during the scientific session of the 26th Annual Meeting of the American Society of Breast Surgeons (ASBrS) in Las Vegas, NV, to be held from April 30 to May 4, 2025.
In November 2024, Perimeter reported positive topline results from the pivotal study, designed to support its planned FDA premarket approval (PMA) submission for marketing the Perimeter B-Series for BCS. The company intends to submit its FDA PMA application in early 2025.
According to Perimeter, the detailed trial results are subject to an embargo policy, which restricts the release of all scientific abstracts accepted for oral or poster presentations at ASBrS 2025, along with press releases and the Society’s Official Proceedings, until 1:00 pm PST on May 1, 2025.
The full abstract will be published by the Annals of Surgical Oncology and released following the oral presentation by Dr. Alastair Thompson, the trial’s primary principal investigator, surgeon and professor. Dr. Thompson serves as section chief of breast surgery, Olga Keith Wiess Chair of Surgery at Baylor College of Medicine, and Breast Cancer Program leader at the Dan L Duncan Comprehensive Cancer Center. The Annals of Surgical Oncology is a top-tier journal in oncology and surgery, featuring original research on the latest advances in oncology surgery.
Adrian Mendes, CEO of Perimeter, commented, “It is a great honor to be selected by the ASBrS to present the detailed results of our pivotal trial for the first time at its prestigious annual meeting, and we are pleased this comes as we continue to work toward obtaining regulatory approval to market our next-generation, AI-enabled OCT system in the U.S.”
“Adding an AI assistant will help surgeons more easily utilize our ground-breaking wide-field OCT technology, which provides high-resolution clarity to visualize margins in real-time in the operating room. We believe increasing breast cancer surgeon awareness of this important innovation through participation in important forums like ASBrS 2025 will go a long way towards advancing the technology’s future adoption,” Mr. Mendes concluded.
